AKROSWISS
17.5.2021 10:02:05 CEST | Business Wire | Press release
Akroswiss is developing an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic seizures. In April, the Swiss start-up has raised several million Swiss Franc in a strategic seed funding round. The funding will fuel R&D to fulfill EMAs requirements to obtain EU marketing authorization for the product.
The majority of Akroswiss’ new funding came from financial investors, the family investment group Linsi, with radiologist and primary user Prof. Dr. med. Bernhard Schuknecht as well as existing investor Walter P. Hölzle also participating in the round. The board has therefore, been extended to seat the new investor groups. Marc Froehlich, former pharma strategy consultant, will operationally lead the company in the role of CEO. Akroswiss will use the new funds to further product development, conduct clinical studies, and initiate the medical device regulatory process to complement EMA’s requirements for data package submission.
Prof. Dr. med. Bernhard Schuknecht highlights: “In our radiology institute Midazolam based nasal spray has been applied for many years during diagnostic examinations. The spray enables adequate resolution of anxiety and sedation and therefore, facilitates patients’ examinations. Akroswiss bi-dose spray is easy to administer and more hygienic than any other solution. Relief of anxiety by endonasal administration is a safe, effective route to improve patients’ comfort and image quality without the necessity of an intravenous line.
An additional advantage of Akroswiss bi-dose nasal spray is the emergency endonasal administration of midazolam in patients with a sudden onset seizure. Thus, a safe route of endonasal administration on an emergency basis may effectively prevent potential harmful injuries and progression into a potential life-threatening seizure status.
To make this product available for more patients in need, a European marketing authorization is required. I believe Akroswiss and its team are best positioned to reach this within reasonable time.”
Akroswiss has successfully developed and tested a unique Bi-dose nasal drug delivery device for Midazolam with a first-class 360° functionality. The development of these Midazolam medicines comes in two independent indications: (1)Product for premedication ahead of diagnostic and therapeutic interventions against claustrophobia and restlessness, (2) product for the rescue treatment in epileptic seizure patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lufthansa Selects Alcohol-Free Gewürztraminer Made with Solos Technology for Premium Allegris Business Class Experience11.11.2026 11:55:00 CET | Press release
German winery Bergdolt-Reif & Nett's BREAKAWAY Gewürztraminer selected following a blind tasting, combining winemaking expertise with Solos' dealcoholisation and patented aroma recovery technology. Lufthansa has selected BREAKAWAY Gewürztraminer, an alcohol-free wine from German winery Bergdolt-Reif & Nett, for its Allegris Business Class. Made using Solos technology, the wine was chosen following a blind tasting and is scheduled to be served from November 2026 to January 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111810839/en/ BREAKAWAY Gewürztraminer by Bergdolt-Reif & Nett, made with Solos technology. The selection marks a milestone for both partners, bringing their expertise to Lufthansa's premium passengers. Where winemaking meets innovation BREAKAWAY Gewürztraminer is made from a late-harvest wine, chosen for its distinctive aromatic character. Bergdolt-Reif & Nett, a fifth-generation family winery in Germ
Quectel SP900BF-AP Smart Module Sets the Pace for Edge AI with 100 TOPS of Computing Power11.11.2026 10:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced the SP900BF-AP, a smart module that lets robots, inspection systems and edge gateways run large AI models on the device itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111252890/en/ Quectel SP900BF-AP smart module sets the pace for Edge AI with 100 TOPS of computing power Built on the Qualcomm Dragonwing™ IQ-9075 Processor and delivering up to 100 TOPS of on-device AI compute, the module enables industrial OEMs to integrate advanced AI directly into their products, reducing latency, bandwidth costs and data privacy risks associated with cloud-based processing. By processing data locally, manufacturers can support real-time robotics, automated inspection and other demanding industrial applications while retaining greater control over sensitive production data. Long-term hardware availability also helps meet the extended product l
Quectel Expands 5G Antenna Portfolio With Ten Versatile Combo Solutions, From Compact 2-In-1 to Rugged 9-In-1 Designs11.11.2026 10:00:00 CET | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces ten external combo antennas that combine 5G with GNSS, Wi-Fi or both in a single housing. Instead of specifying, fitting and testing a separate antenna for each radio, device makers can choose one unit matched to the size, technology mix and operating environment of their deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111461614/en/ Quectel expands 5G antenna portfolio with ten versatile combo solutions, from compact 2-in-1 to rugged 9-in-1 designs Across the family, each antenna combines multiple omnidirectional elements with high isolation between them to limit self-interference. Most models cover 5G from 600MHz to 6000MHz and remain backward compatible with 4G, 3G, 2G, LTE Cat-M and NB-IoT networks. All support screw mounting, some also adhesive mounting, and housings are built for outdoor use with ratings from IP65 up to IP69K. “Ev
Lattice and NXP Deliver Flexible, Secure Computing Solution for the Industrial Edge10.11.2026 22:00:00 CET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced the Lattice NXP PCIe® Companion solution, jointly enabled and promoted with NXP® Semiconductors. Pairing NXP’s i.MX 95 applications processor with Lattice Nexus™-based FPGAs over PCIe, the solution addresses the real-time connectivity, deterministic I/O, and security challenges in industrial automation, robotics, and intelligent edge applications. The joint solution is available in Lattice CertusPro™-NX or Lattice Certus™-NX configurations as companion chips to NXP i.MX 95 SoC compute processors, deepening a long-standing collaboration between Lattice and NXP spanning industrial, data center, and networking applications. The Lattice FPGA adds low latency, deterministic I/O alongside the NXP applications processor, delivering combined capabilities across real-time processing, AI, and custom I/O to help customers modernize aging designs for new interface standards. It supports e
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10.11.2026 19:14:00 CET | Press release
PIMJETMI is a new once-daily oral systemic treatment option for certain U.S. patients with symptomatic tenosynovial giant cell tumor (TGCT)In the Phase 3 MANEUVER trial, PIMJETMI demonstrated early1 and durable2 tumor response with clinically meaningful improvements in all clinical outcome assessments, including physical function and painPIMJETMI has shown high objective response rate (ORR) with a manageable safety profileNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significant
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom